A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

Published:2019-11-15 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Rammensee Hans-Georg,Wiesmüller Karl-Heinz,Chandran P. Anoop,Zelba Henning,Rusch Elisa,Gouttefangeas Cécile,Kowalewski Daniel J.,Di Marco Moreno,Haen Sebastian P.,Walz Juliane S.,Gloria Yamel Cardona,Bödder Johanna,Schertel Jill-Marie,Tunger Antje,Müller Luise,Kießler Maximilian,Wehner Rebekka,Schmitz Marc,Jakobi Meike,Schneiderhan-Marra Nicole,Klein Reinhild,Laske Karoline,Artzner Kerstin,Backert Linus,Schuster Heiko,Schwenck Johannes,Weber Alexander N. R.,Pichler Bernd J.,Kneilling Manfred,la Fougère Christian,Forchhammer Stephan,Metzler Gisela,Bauer Jürgen,Weide Benjamin,Schippert Wilfried,Stevanović Stefan,Löffler Markus W.^ORCID

Funder

FP7 Ideas: European Research Council

Ernst Jung Preis

Faculty of Medicine Carl Gustav Carus of the Technische Universität Dresden

Deutsche Forschungsgemeinschaft

Federal State Baden-Württemberg

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0796-5.pdf

Reference50 articles.

1. Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577–81.

2. Luksza M, Riaz N, Makarov V, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2017;551(7681):517–20.

3. Panda A, Betigeri A, Subramanian K, et al. Identifying a clinically applicable mutational burden threshold as a potential biomarker of response to immune checkpoint therapy in solid tumors. JCO Precis Oncol. 2017;2017.

4. Rini BI, Stenzl A, Zdrojowy R, et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(11):1599–611.

5. Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18(8):1254–61.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges;Acta Pharmaceutica Sinica B;2024-09

2. iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens;Frontiers in Oncology;2024-08-26

3. An Unconventional Case Study of Neoadjuvant Oncolytic Virotherapy for Recurrent Breast Cancer;Vaccines;2024-08-23

4. Decoding Toll-like receptors: Recent insights and perspectives in innate immunity;Immunity;2024-04

5. FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion;Frontiers in Oncology;2024-03-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3